Brief: Aeon Biopharma Announces Topline Results From Phase 2 Trial Of Abp-450 (Prabotulinumtoxina) For The Preventive Treatment Of Episodic Migraine
19/10/2023 21:58
Oct 19 (Reuters) - Aeon Biopharma Inc AEON.A :
* AEON BIOPHARMA ANNOUNCES TOPLINE RESULTS FROM PHASE 2
TRIAL OF
ABP-450 (PRABOTULINUMTOXINA) FOR THE PREVENTIVE TREATMENT OF
EPISODIC MIGRAINE
* AEON BIOPHARMA INC - STUDY DEMONSTRATED STATISTICAL
SIGNIFICANCE
ON MULTIPLE SECONDARY AND EXPLORATORY ENDPOINTS
* AEON BIOPHARMA - TOTALITY OF DATA SHOWED EVIDENCE OF DOSE
RESPONSE FAVORING HIGHER 195 UNITS ARM, SUPPORTS DECISION TO
ADVANCE INTO PHASE 3
* AEON BIOPHARMA INC: STUDY DID NOT MEET STATISTICAL
SIGNIFICANCE
VERSUS. PLACEBO
* AEON BIOPHARMA - ANTICIPATE COMPLETING ENROLLMENT FOR
PHASE 2
TRIAL FOR PREVENTIVE TREATMENT OF CHRONIC MIGRAINE IN Q4'23,
EXPECT TOPLINE DATA IN 2H24
Source text for Eikon: ID:nGNX2ZWQ7g
Further company coverage: AEON.A
Recent news on Aeon Biopharma
See all newsBrief: Aeon Biopharma Reports bpd Type 2A Meeting With FDA And Shareholder Approval Of The November Transactions
Brief: Aeon Biopharma Announces Execution Of Exchange Agreement With Daewoong
Brief: Aeon Biopharma Announces First Closing Of Pipe Investment And Provides Update On FDA Type 2A Meeting Scheduling
Brief: Aeon Biopharma Announces FDA bpd Type 2A Meeting For Abp-450 On November 19
Brief: Aeon Biopharma Announces CEO Transition